FDA Information
Doxepin was originally approved by the FDA in 1969. A topical formulation of doxepin (ZonalonŽ) was approved for pruritus associated with eczema in 1994.
On October 15, 2004 the FDA directed manufacturers of all antidepressants to include a Black Box warning, expanded warning statements, and clinical trial results detailing the increased risk of suicidality in children and adolescents.
Why is this medication prescribed?
Dosage and using this medicine
What special precautions should I follow?
What should I do if I forget a dose?
What side effects can this medication cause?